Cargando…

Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy

BACKGROUND: Tight monitoring of efficacy and safety of anticoagulants such as warfarin is imperative to optimize the benefit-risk ratio of anticoagulants in patients. The standard tests used are measurements of prothrombin time (PT), usually expressed as international normalized ratio (INR), and act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartmann, Sonja, Biliouris, Konstantinos, Lesko, Lawrence J., Nowak-Göttl, Ulrike, Trame, Mirjam N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381140/ https://www.ncbi.nlm.nih.gov/pubmed/32765265 http://dx.doi.org/10.3389/fphar.2020.01041

Ejemplares similares

Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network
por: Hartmann, S, et al.
Publicado: (2016)

The Role of Warfarin and Rivaroxaban in the Treatment of Cerebral Venous Thrombosis
por: Fayyaz, Muniba, et al.
Publicado: (2019)

MatVPC: A User-Friendly MATLAB-Based Tool for the Simulation and Evaluation of Systems Pharmacology Models
por: Biliouris, K, et al.
Publicado: (2015)

Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency
por: Ameku, Koken, et al.
Publicado: (2018)

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions
por: Margolis, Jay M., et al.
Publicado: (2016)

Perspective on the State of Pharmacometrics and Systems Pharmacology Integration
por: Trame, Mirjam N., et al.
Publicado: (2018)

Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban
por: Piati, Polyana Klomfass, et al.
Publicado: (2019)

A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia
por: Derseh, Manaye Tamrie, et al.
Publicado: (2021)

Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study
por: Khorvash, Fariborz, et al.
Publicado: (2021)

Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China
por: Yang, Li, et al.
Publicado: (2020)

Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
por: Stolz, Leonie, et al.
Publicado: (2017)

Rivaroxaban versus warfarin for the management of left ventricle thrombus
por: Albabtain, Monirah A., et al.
Publicado: (2021)

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
por: Biliouris, Konstantinos, et al.
Publicado: (2018)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report
por: Schiavoni, Mario, et al.
Publicado: (2016)

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
por: Sherid, Muhammed, et al.
Publicado: (2016)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Ethnic Diversity and Warfarin Pharmacogenomics
por: Asiimwe, Innocent G., et al.
Publicado: (2022)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

Warfarin and Rivaroxaban Duplication: A Case Report and Medication Error Analysis
por: Fusco, Julie A., et al.
Publicado: (2015)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Rivaroxaban for the treatment of cerebral venous thrombosis
por: Esmaeili, Sara, et al.
Publicado: (2021)

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect
por: Ing Lorenzini, Kuntheavy, et al.
Publicado: (2016)

Editorial: The emerging discipline of quantitative systems pharmacology
por: Leil, Tarek A., et al.
Publicado: (2015)

Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation
por: Limdi, Nita A.
Publicado: (2012)

Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models
por: Zhang, X‐Y, et al.
Publicado: (2015)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects
por: Moore, Kenneth Todd, et al.
Publicado: (2015)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke
Publicado: (2010)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
por: Liu, Zhuang, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease
por: Feng, Tianyu, et al.
Publicado: (2022)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jlhrt3e8gu6bo5h6cqmqk48ocb